In order to validate these results, we analyzed ANXA2 gene expression data from two independent cohorts of GBM patients (the TCGA dataset [26, 27] and GSE13041 [28]) and correlated its expression to patient outcome. The gene discussed is ANXA2; the disease is glioblastoma.